Atlas Trials

Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD

Clinical trial NCT04058535 · COMPLETED

Trial details

NCT number
NCT04058535
Sponsor
Alteogen, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2020-02-05
Primary completion
2020-12-22
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.